| [June 20, 2016] |
 |
Favourable Commercial Environment Awaits MedImmune Anti-Flu Candidate - Research and Markets
Research and Markets has announced the addition of the "Anti-Infective
Drug News Issue 340" report to their offering.
A number of factors are serving to drive up cancer drug spending despite
fierce and widespread criticism of this trend. The genericisation of
some premium brands will provide some respite from growing spend.
However, this will not be enough to offset the cost burden presented by
the continued wave of increasingly targeted single-agents and
combinations, as well as longer treatment durations resulting from
better outcomes. Express Scripts' steps towards value-based pricing are
indicative of wider market changes, not just in the US, but globally, in
an attempt to control spiralling healthcare expenditure.
Key Topics Covered:
-
Favourable Commercial Environment Awaits MedImmune Anti-Flu Candidate
-
FDA Approves Elusys' Anthim For Anthrax
-
Prevnar 13 Patent Attack Will Pressure Indian Patent Office
-
Summit's Ridiilazole Preserves Gut Microbiome In Phase II CoDIFy Trial
-
Cellceutix Seeks SPA Approval For Brilacidin Phase III Trial In ABSSSIs
-
Takeda's H. Pylori Regimens Approved In Japan
-
Teva Canada Launches Tobramycin Inhalation Solution
-
FDA Accepts Allergan's Avycaz sNDA For Review
-
Altan Enters Caspofungin Licensing Agreement
-
AureoGen/Merck Enter Licensing Deal For Novel Antifungal Drugs
-
FDA Grants ODD For Matinas' NTM Infection Candidate
-
ViveBio Enters Collaboration To Support Phase III Dengue Vaccine
Studies
-
Shionogi/Roche Collaborate On Anti-Flu Drug Development
-
CHMP Recommends Approval Of Viekirax+Exviera And Descovy
-
EMA (News - Alert) Validates Gilead's Tenofovir Alafenamide MAA For HBV
-
Brincidofovir Still Has A Future In CMV Prevention
-
Zika Outbreak Sparks Diagnostics Development Rush
-
Prize Fund Concept Rethinks Innovation/Reward Model
-
Teva Canada Launches Abacavir+Lamivudine
-
Gilead's F/TAF Franchise Gaining Commercial Momentum (News - Alert)
-
Gilead To Maintain HIV Dominance Despite ViiV Challenges
-
Isentress Phase III ONCEMRK Trial Meets Primary Endpoint
-
Expanding Antiretroviral Market To Provide Revenue Earning
Opportunities
-
Commitment To Vaccine Supply Will Create Opportunities For Drugmakers
-
Paediatric Hexavalent Vaccine Approved For Sale In EU
-
Sanofi/Merck To End European Joint Vaccines Operations
-
ViiV Completes Acquisition Of BMS' R&D HIV Assets
For more information visit http://www.researchandmarkets.com/research/wjmq6j/antiinfective
View source version on businesswire.com: http://www.businesswire.com/news/home/20160620005619/en/
[ Back To TMCnet.com's Homepage ]
|
